DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors
Neuroendocrinology · 2024
DOI: 10.1159/000533692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, 2024. Verfasst von Paulina Kober und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatotrophs, Growth Hormone-Secreting Pituitary Adenoma, Pituitary Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Introduction
Growth hormone secretion by sporadic somatotroph neuroendocrine pituitary tumors (PitNETs) is a major cause of acromegaly. These tumors are relatively heterogenous in terms of histopathological and molecular features. Our previous transcriptomic profiling of somatotroph tumors revealed three distinct molecular subtypes. This study aimed to investigate the difference in DNA methylation patterns in subtypes of somatotroph PitNETs and its role in distinctive gene expression.
Methods
Genome-wide DNA methylation was investigated in 48 somatotroph PitNETs with EPIC microarrays. Gene expression was assessed with RNAseq. Bisulfite pyrosequencing and qRT-PCR were used for verifying the results of DNA methylation and gene expression.
Results
Clustering tumor samples based on methylation data reflected the transcriptome-related classification. Subtype 1 tumors are densely granulated without GNAS mutation, characterized by high expression of NR5A1 (SF-1) and GIPR. The expression of both genes is correlated with specific methylation of the gene body and promoter. This subtype has a lower methylation level of 5′ gene regions and CpG islands than the remaining tumors. Subtype 2 PitNETs are densely granulated and frequently GNAS-mutated, while those in subtype 3 are mainly sparsely granulated. Methylation/expression analysis indicates that ∼50% genes located in differentially methylated regions are those differentially expressed between tumor subtypes. Correlation analysis revealed DNA methylation-controlled genes, including CDKN1B, CCND2, EBF3, CDH4, CDH12, MGMT, STAT5A, PLXND1, PTPRE, and MMP16, and genes encoding ion channels and semaphorins.
Conclusion
DNA methylation profiling confirmed the existence of three molecular subtypes of somatotroph PitNETs. High expression of NR5A1 and GIPR in subtype 1 tumors is correlated with specific methylation of both genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Neurosurgery, Military Institute of Medicine, Warsaw, Poland.
- Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Zitieren
APA
Kober, P., Rymuza, J., Baluszek, S., Maksymowicz, M., Nyc, A., Mossakowska, B. J., Zieliński, G., Kunicki, J., & Bujko, M. (2024). DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors. Neuroendocrinology. https://doi.org/10.1159/000533692
Vancouver
Kober P, Rymuza J, Baluszek S, Maksymowicz M, Nyc A, Mossakowska BJ, et al. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors. Neuroendocrinology. 2024. doi:10.1159/000533692
BibTeX
@article{Kober2024,
author = {Kober, Paulina and Rymuza, Julia and Baluszek, Szymon and Maksymowicz, Maria and Nyc, Aleksandra and Mossakowska, Beata J and Zieliński, Grzegorz and Kunicki, Jacek and Bujko, Mateusz},
title = {DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors},
journal = {Neuroendocrinology},
year = {2024},
doi = {10.1159/000533692}
}
EUVIMED